复发或难治性急性髓系白血病的FLAG-Ida方案与柔红霉素联合克拉屈滨方案的随机比较:英国NCRI AML17试验结果
英国NCRI AML17试验中,94例复发或难治性急性髓系白血病患者随机接受最多三个疗程的柔红霉素/克拉屈滨(DClo)或FLAG-Ida方案治疗,旨在桥接移植。两组完全缓解率均为74%,57%患者接受移植,5年总生存率无显著差异(DClo组21% vs FLAG-Ida组22%)。未接受移植者无生存超过21个月。
要点
- 复发/难治AML患者中DClo与FLAG-Ida的完全缓解率均为74%,组间无差异。
- 57%患者接受移植,两组无差异;5年总生存DClo组21% vs FLAG-Ida组22%,无显著差异。
- 未接受移植者无生存超过21个月;含311例高危患者的 stratified 分析显示FLAG-Ida一致的治疗获益。
核心结论
- 在复发或难治性AML患者中,DClo与FLAG-Ida的完全缓解率、移植率和5年总生存率均无显著差异。
- 未接受移植的患者无生存超过21个月。
- 包含311例第一疗程后高危患者的 stratified 分析显示FLAG-Ida一致的治疗获益。
研究设计与样本
- 英国NCRI AML17试验中的随机比较,纳入94例复发或难治性AML患者。
- 患者通常小于60岁,细胞遗传学风险主要为预后良好或中等。
- 随机接受最多三个疗程的DClo或FLAG-Ida治疗,目标是桥接移植。
主要发现
- 完全缓解率74%,两组间无差异。
- 57%患者接受移植,两组间无差异。
- 5年总生存率DClo组21% vs FLAG-Ida组22%,无显著差异。
- 未接受移植者无生存超过21个月。
- 包含311例第一疗程后高危患者的 stratified 分析显示FLAG-Ida一致的治疗获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prognosis for younger patients with relapsed acute myeloid leukaemia (AML) is generally dismal. Allogeneic stem cell transplantation is the preferred therapy for these patients. As part of the UK NCRI AML17 trial, daunorubicin/clofarabine (DClo) was compared with fludarabine, cytarabine, granulocyte colony-stimulating factor with idarubicin (FLAG-Ida) in 311 patients designated high-risk following course one of induction therapy, which has previously been reported. We now report the results of the same randomisation in patients who were refractory to two induction courses or subsequently relapsed. A total of 94 relapsed or refractory AML patients, usually less than 60 years of age and with mainly favourable or intermediate-risk cytogenetics, were randomised to receive up to three courses of DClo or FLAG-Ida, with the aim of proceeding to transplant. Complete remission was achieved in 74% of patients with no difference between the arms. Overall, 57% of patients received a transplant with no difference between the arms, likewise overall survival at five years showed no significant difference (21% for DClo vs. 22% for FLAG-Ida). No patient who did not receive a transplant survived beyond 21months. A stratified analysis including the 311 post course 1 high-risk patients who underwent the same randomisation showed a consistent treatment benefit for FLAG-Ida.
引用
- Russell NH, Hills RK, Kjeldsen L, et al. A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial. Br J Haematol. 2022. PMID: 35388465. doi:10.1111/bjh.18195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。